Drugbank Logo

Showing drug card for Ethiodized oil (DB00965)

Legend: drug field target field enzyme field

Version 2.5
Creation Date 2005-06-13 13:24:05
Update Date 2009-06-23 18:07:24
Primary Accession Number DB00965
Secondary Accession Number
  • APRD00960
Name Ethiodized oil
Drug Type
  • Approved
  • Small Molecule
Description Ethiodized oil is used by injection as a radio-opaque contrast agent. It is composed of iodine combined with ethyl esters of fatty acids of poppyseed oil, primarily as ethyl monoiodostearate and ethyl diiodostearate. The precise structure is not known.
Synonyms
  1. EOE 13
Brand Names
  1. Ethiodol
Brand Mixtures Not Available
Chemical IUPAC Name Not Available
Chemical Formula C20H38O2I
Chemical Structure Structure
CAS Registry Number 8008-53-5
InChI Identifier Not Available
InChI Key Not Available
KEGG Drug D04082 Link Image
KEGG Compound Not Available
PubChem Compound Not Available
PubChem Substance 167250 Link Image
ChEBI ID Not Available
PharmGKB ID Not Available
HET ID Not Available
GenBank ID Not Available
Drug ID Number [DIN] 00386685 Link Image
RxList Link http://www.rxlist.com/cgi/generic2/ethiodol.htm Link Image
PDRhealth Link Not Available
Wikipedia Link http://en.wikipedia.org/wiki/Ethiodized_oil Link Image
FDA Label Not Available
Material Safety Data Sheet (MSDS)
Synthesis Reference Not Available
Average Molecular Weight 437.4190
Monoisotopic Molecular Weight 437.1916
State Liquid
Melting Point 125oC (boiling point at 8mm Hg)
Experimental Water Solubility Insoluble Source: PhysProp
Predicted Water Solubility Not Available Calculated using ALOGPS
Experimental LogP/Hydrophobicity Not Available Source: PhysProp
Predicted LogP Not Available Calculated using ALOGPS
Experimental LogS Not Available
Predicted LogS Not Available Calculated using ALOGPS
Experimental Caco2 Permeability Not Available
pKa/Isoelectric Point Not Available
Mass Spectrum Not Available
MOL File Not Available
SDF File Not Available
PDB File Not Available
Experimental PDB ID Not Available
Isomeric SMILES Not Available
Canonical SMILES Not Available
Drug Category
  • Antineoplastic Agents
  • Contrast Media
ATC Codes Not Available
AHFS Codes Not Available
Indication For use as a radio-opaque medium for hysterosalpingography and lymphography, and as an antineoplastic agent when part of the iodine is 131-I.
Pharmacology There has been little detailed investigation of the metabolic fate of ethiodized oil in either man or animals. However, the fate of ethiodized oil following Iymphangiography in dogs has been reported. Koehler et al. employed I131-tagged ethiodol for lymphangiography in dogs and analyses of individual organs at various time intervals were done. The investigators reported an average of only 25% of the injected medium was retained in the lymphatics at the end of three days. An average of 50% was recovered from the lungs. They found the remainder of injected activity was fairly uniformly distributed throughout the body. Urinary excretion in the form of inorganic iodine was revealed as the chief mode of iodine loss from the system.
Mechanism of Action Ethiodized oil is selectively retained in tumor vessels for long periods, and is used for imaging organs such as liver, lung, stomach, and thyroid. Labeled with I-131 or other beta emitters (Y-90 or P-32), ethiodized oil can deliver a high internal radiation dose to certain tumors with minimal effect on healthy tissues.
Absorption Not Available
Toxicity Intravenous LD50 in dog is 1580mg/kg. Symptoms of overdose include dyspnea and change in clotting factors.
Protein Binding Not Available
Biotransformation Not Available
Half Life Not Available
Dosage Forms
Form Route
Injection, solution Intralymphatic
Patient Information Not Available
Contraindications Show Link Image
Interactions Show Link Image
Drug Interactions Not Available
Food Interactions Not Available
Pathways Not Available
General References
  1. [PubMed Link Image]
  2. Wikipedia Link Image
  3. RxList Link Image
Organisms Affected
  • Humans and other mammals

This project is supported by Genome Alberta & Genome Canada, a not-for-profit organization that is leading Canada's national genomics strategy with $600 million in funding from the federal government. This project is also supported in part by GenomeQuest, Inc., an enterprise genomic information company serving the life science community.